Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, which are the most common oncogenic drivers in human cancers [7] - The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer [7] - Silexion is advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies [7] Public Offering Details - Silexion Therapeutics announced the pricing of a public offering of 3,703,703 ordinary shares (or equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of 1.35 per share, are exercisable immediately upon issuance, and will expire five years from the date of issuance [5] - The gross proceeds from the offering, before deducting fees and expenses, are expected to be approximately $5.0 million [6] - The net proceeds will be used to advance the company's pre-clinical studies and for general corporate purposes [6] Regulatory and Offering Information - The securities are being offered pursuant to a registration statement on Form S-1 (File No. 333-282932), which was declared effective by the SEC on January 15, 2025 [2] - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [6] - The closing of the offering is expected to occur on or about January 17, 2025, subject to customary closing conditions [5]
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering